CORRECTION

This article refers to:

Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective

Article title: Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective

Authors: Pierre Levy, David M. Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin and Jean-Baptiste Briere

Journal: JOURNAL OF MARKET ACCESS & HEALTH POLICY

Bibliometrics: Volume 7, Number 1

DOI: https://doi.org/10.1080/20016689.2018.1564506

When the above article was first published online, the author name ‘David M. Smadja’ and his affiliation was published incorrectly. The author names and affiliation have now been corrected in the online version.

Pierre Levy^a, David M. Smadja^b,c,d, Julie Dorey^e, Mondher Toumi^f, Anna-Katharina Meinecke^g, Kevin Bowrin^h and Jean-Baptiste Briere^g

^aDepartment of Economics and Management of Health Organisations, The University of Paris Dauphine, Paris, France;

^bDepartment of Medicine, Paris Descartes University, Sorbonne Paris City, Paris, France;

^cUMR-S1140, Inserm, Paris, France;

^dHematology Department, AP-HP Georges Pompidou European Hospital, Paris, France;

^eCreativ Ceutical, Paris, France;

^fMedical School, Laboratory of Public Health, The University of the Mediterranean,

Marseilles, France;

^gBayer AG, Berlin, Germany;

^hBayer Plc, Reading, UK